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ABSTRACT
To determine whether circulating insulin-like growth factor (IGF)-I has a role in hematopoiesis, we examined
hematologic parameters in mice with markedly reduced serum levels resulting from a liver-specific inactivation
of the IGF-I gene. These mice have normal postnatal growth and development, suggesting that local produc-
tion of IGF-I can maintain anabolic effects. Liver-specific IGF-I–deficient (LID) mice were compared with
control littermates with regard to hematopoietic parameters. Spleen cellularity was decreased in the LID mice
compared with control mice. Spleen myeloid progenitors, as determined by colony-forming units–granulocyte/
monocyte (CFU-GM) and colony-forming units–high proliferative potential (CFU-HPP), were significantly
decreased in the LID mice. Immune parameters, as indicated by the absolute number of B and T cells, did not
significantly differ between the knockout and control mice. In contrast to the decreased cellularity and
myelopoiesis in the spleen, bone marrow cellularity was not different between the 2 groups, but the total
femoral content of CFU-GM and CFU-HPP was significantly increased in the LID mice. The decrease in
splenic myelopoiesis was not due to the inability of progenitors to exit the bone marrow, because CFU-GM and
burst-forming units–erythroid were significantly increased in the blood of LID mice compared with normal
littermates. Administration of exogenous IGF-I to the LID mice for 4 days partially restored myelopoietic
parameters in the spleen. Liver production of IGF-I and, therefore, normal serum levels of this hormone,
although not necessary for general organ growth and development, seems necessary for survival or transition
of myeloid progenitors into the spleen.
© 2004 American Society for Blood and Marrow Transplantation
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The insulin-like growth factors (IGFs) are mem-
ers of the insulin-related peptide family, which in-
ludes IGF-I, IGF-II, and insulin [1]. IGF-I and IGF-
I, acting through the IGF-I receptor, are essential for
ormal growth and development [2–4].
he content of this publication does not necessarily reﬂect the views or
olicies of the Department of Health and Human Services, nor does
ention of trade names, commercial products, or organizations imply
ndorsement by the US government.
2The original somatomedin hypothesis suggested
hat growth hormone (GH), produced in the anterior
ituitary, stimulated the production and secretion of
GF-I by the liver, which then mediated the effects of
H in various tissues. However, it has been recently
hown that liver-derived IGF-I, the major source of
his hormone in the circulation, is not needed for
ormal postnatal growth [5]. Local production of
GF-I active either in paracrine/autocrine or endo-
rine fashion seems to be sufﬁcient for GH-induced
omatic growth [5,6].IGF-I has been shown to promote hematopoietic
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IGF-I and Splenic Hematopoiesis in Mice
Bell growth in vitro [7], but the role of endogenous
GF-I in hematopoiesis is unclear. Examination of the
ole of IGF-I in hematopoiesis through the use of null
utation experiments has been hampered by the se-
erity of the growth retardation, which complicates
valuation of bone and hematopoiesis in IGF-I–deﬁ-
ient animals.
Administration of either GH or IGF-I has been
hown to improve hematopoietic function in the bone
arrow and spleens in aged rats [8] after myelosup-
ression [9,10] or after bone marrow transplantation
11]. Although these agents can improve recovery of
tressed or injured marrow, previous studies have also
hown that administration or overexpression of GH or
GF-I results in increased splenic myelopoiesis, with
ncreases in DNA synthesis and hematopoietic pro-
enitors but does not change the cellular content of
he bone marrow [9,10,12]. In this liver-speciﬁc IGF-
–deﬁcient (LID) model, which exhibits low serum
GF-I and has a 4.5-fold increase in serum GH [5], we
ere able to examine the effect of increased serum
H with concomitant low serum IGF-I levels on
ematopoiesis to dissect the putative overlapping roles
f GH and IGF-I on hematopoiesis.
ATERIALS AND METHODS
ice
Mice with a liver-speciﬁc deletion of the igf1 gene
ere generated by using the Cre/loxP system as pre-
iously described [5]. Sex-matched littermates with
he igf1 gene ﬂanked by loxP sites but lacking the
re-transgene and thus expressing liver-speciﬁc IGF-I
erved as controls [5]. Mice were bred and maintained
nder speciﬁc pathogen-free conditions in the Na-
ional Institutes of Health Bethesda facility. Male mice
t 4 weeks of age were used for immune and hemato-
oiesis studies. These studies were approved by the
nimal Care and Utilization Committee of the Na-
ional Institute of Diabetes and Digestive and Kidney
isease. All animals used in this research project were
ared for and used humanely according to the follow-
ng policies: the US Public Health Service Policy on
umane Care and Use of Animals (1996); the Guide
or the Care and Use of Laboratory Animals (1996); and
he US Government Principles for Utilization and
are of Vertebrate Animals Used in Testing, Re-
earch, and Training (1985). All National Cancer In-
titute–Frederick animal facilities and the animal pro-
ram are accredited by the Association for Assessment
nd Accreditation of Laboratory Animal Care Inter-
ational.
ell Preparation
Bone marrow cells were extracted by ﬂushing
one marrow plugs from femurs with an RPMI me- g
B&MTium–ﬁlled syringe ﬁtted with a 22-gauge hypodermic
eedle, and single-cell suspensions were prepared by
epeated aspirations of the plugs. Single-cell suspen-
ions of spleens were prepared by gently crushing the
rgans in RPMI-1640 supplemented with 10% fetal
ovine serum, l-glutamine, and antibiotics (100
/mL penicillin and streptomycin). Spleen cell prep-
rations and heparinized peripheral blood cells were
reated with ACK lysis buffer (Quality Biologicals,
aithersburg, MD) to remove red blood cells. Nucle-
ted spleen, bone marrow, and peripheral blood cell
ounts were performed with a Z1 Coulter counter
Coulter Electronics, Hialeah, FL).
olony Assays
For colony-forming units–granulocyte/monocyte
CFU-GM) and burst-forming units–erythroid
BFU-E), bone marrow cells, spleen cells, or periph-
ral blood cells were plated in 35-mm petri dishes at a
oncentration of 5  104, 5  105, or 3  105 nucle-
ted cells per plate, respectively. Colony formation
as stimulated with 10 ng/mL recombinant murine
ranulocyte-macrophage colony-stimulating factor,
0 ng/mL recombinant murine interleukin (IL)-3
Peprotech Inc., Rocky Hill, NJ), and 5 U/mL eryth-
opoietin (Stem Cell Technologies, Vancouver, Brit-
sh Columbia, Canada). Plates were incubated at 37°C
or 7 days in 5% CO2 and 100% humidity. Colonies
ere deﬁned as aggregates of more than 50 cells.
olonies that contained only red blood cells were
cored as BFU-E. Colonies that consisted of only
hite blood cells were scored as CFU-GM. For col-
ny-forming unit–high proliferative potential (CFU-
PP), bone marrow cells or spleen cells were plated in
0-mm petri dishes at a concentration of 2.5  104 or
 105 nucleated cells per plate, respectively. Colony
ormation was stimulated with 20 ng/mL recombinant
uman IL-6, 20 ng/mL recombinant murine IL-3,
nd 100 ng/mL stem cell factor. Plates were incubated
t 37°C for 10 days in 5% CO2 and 100% humidity.
FU-HPP were deﬁned as colonies with a diameter
f 2 mm and an estimated cell number of 10 000.
low Cytometry
Lymphocyte subsets in the spleen were evalu-
ted by 2-color ﬂow cytometric analysis on a FAC-
can afﬁxed with a 488-nm laser (Becton Dickinson,
ountain View, CA). Spleen cells (106 cells) were
abeled with primary antibody for 20 minutes at
°C, washed, and ﬁxed with 1% paraformaldehyde.
ata were collected on viable lymphocytes on the
asis of forward and side scatter, and 104 cells were
nalyzed for expression of surface markers. Analysis
as performed by using CellQuest software (Becton
ickinson). Monoclonal antibodies (BD Pharmin-
en, San Diego, CA) included ﬂuorescein isothio-
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3yanate– conjugated anti-CD8 monoclonal antibod-
es (clone 53-6.7), anti–immunoglobulin M (clone
6-60.2), and the phycoerythrin-conjugated anti-
odies anti-CD4 (RM4-5) and CD45R (clone RA3-
B2). Isotype-matched controls were used to quan-
ify nonspeciﬁc background binding, which was
ubtracted from all results.
istology
Mice were killed by CO2 asphyxiation. Tissues
ere removed and ﬁxed in 10% buffered neutral for-
alin. Femurs were decalciﬁed. Tissues were embed-
ed in parafﬁn, sectioned at 5 m, and stained with
ematoxylin and eosin. Tissue sections were reviewed
y a veterinary pathologist. s
4GF-I Administration
Mice received subcutaneous injections of recom-
inant human IGF-I (Genentech, San Francisco, CA;
mg/kg) daily for 4 days.
tatistical Analysis
Statistical analysis was performed by using the
tudent t test. Values shown are means  SEM. Dif-
erences of P  .05 were considered signiﬁcant.
ESULTS
Initial examination of LID mice revealed normal
ody and organ development except for a decrease in
igure 1. Decreased splenic myelopoiesis in LID mice. A, Total
umber of nucleated cells per spleen in LID and control mice (P 
05). B, Frequency of committed myeloid (CFU-GM; P  .0005)
nd erythroid (BFU-E; not signiﬁcant) progenitors and primitive
rogenitors (CFU-HPP; P  .001) in the spleens of LID mice and
ontrol littermates. C, Total number of CFU-GM (P  .0005) and
FU-E progenitors and CFU-HPP (P  .001) per spleen in LID
ice compared with control littermates. Results of 4 independent
xperiments with a combined total of 7 mice per group are shown.F
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IGF-I and Splenic Hematopoiesis in Mice
B50% in LID mice compared with control mice con-
aining both loxP-ﬂanked igf1 alleles [5]. Because
GF-I affects immune cell number, function, and he-
atopoiesis (see reviews [13,14]), we investigated the
educed size of the spleen by examining both the
ymphoid and hematopoietic compartments of this
issue. The 22% reduction in nucleated spleen cells
Figure 1A) was consistent with the original observa-
ion of decreased spleen weight in the LID mice rel-
tive to controls [5]. Normal splenic architecture was
aintained in the LID mice (data not shown). In
ddition to normal architecture, the frequencies of T
nd B cells were not signiﬁcantly different between
ID mice and controls (Table 1). These ﬁndings were
ot unexpected because previous reports found no
efect in B- or T-cell development in either lit/lit
ice, which do not secrete GH from the anterior
ituitary, or IGF-I–deﬁcient mice [13,15].
In contrast to the lymphoid compartment of the
pleen, a signiﬁcant reduction in the frequency (Fig-
re 1B) and absolute number of myeloid progenitors
as observed (Figure 1C) in LID mice compared with
ontrols. Both the relatively mature population of
rogenitors, measured by CFU-GM, and the more
mmature population, measured by CFU-HPP, were
ffected (P  .005 and P  .001, respectively). No
igniﬁcant changes in erythroid progenitors were ob-
erved, although a mild relative decrease in the my-
loid to erythroid cell ratio was noted in 2 of 3 histo-
ogic specimens compared with littermate controls.
hese results indicate that the contribution of liver-
erived IGF-I plays an important role in the splenic
yeloid cell compartment.
Investigation of femoral bone marrow hematopoi-
sis revealed normocellular bone marrow in both LID
nd control mice, although increased numbers of
egakaryocytes were present in 2 of 3 LID specimens
data not shown). In agreement with the histologic
xamination of the femurs, there was no signiﬁcant
ifference in the total number of nucleated cells per
able 1. Distribution of Spleen Lymphocytes in LID Mice and
ittermates
Cell Phenotype Control Mice (%) LID Mice (%)
220, immunoglobulin M 35.7  2.1 35.5  1.1*
D4 23.6  1.9 29.3  2.5*
D8 4.7  0.4 4.9  0.8*
pleen cell lymphoid subsets were unaltered in LID mice. Spleno-
cytes from naive animals were labeled with directly conjugated
antibodies and analyzed by ﬂow cytometry. No differences were
observed in the frequency of B cells (B220 and immunoglob-
ulin M) or T cells (CD4 or CD8 subsets). Results of 4
independent experiments with a combined total of 7 mice per
group are shown.
No signiﬁcant difference from control (Student t test).emur in either control or LID mice (Figure 2A). w
B&MTlthough no gross abnormality was observed in the
one marrow, a signiﬁcant increase in both committed
nd primitive progenitors was observed in LID mice
elative to control littermates (Figure 2B and 2C).
eripheral blood cell counts mirrored the bone mar-
ow ﬁndings. Erythrocytes, granulocytes, and mono-
ytes were within normal parameters (data not
hown), whereas the platelet counts were increased
689  75 million platelets per milliliter of peripheral
lood) in the LID animals compared with control
ice (265  11 million platelets per milliliter of pe-
ipheral blood), which is consistent with the increase
n bone marrow megakaryocytes described previously.
aken together, these ﬁndings suggest that the
arked decrease in serum IGF-I in LID mice has a
imited effect on murine bone marrow hematopoiesis
hrough increased myeloid progenitor cell content
nd thrombocytosis.
We hypothesized that the presence of increased
umbers of primitive and myeloid progenitors in the
one marrow may be due to a decreased ability of
hese cells to migrate out of the bone marrow and into
he circulation of animals with low serum IGF-I. This
nding would also account for a decrease in primitive
nd myeloid progenitors in the spleen. To test this
ypothesis, the number of hematopoietic progenitors
n the peripheral blood of LID mice and their litter-
ates was determined. Contrary to our expectations,
e observed a 3-fold increase in CFU-GM and a
-fold increase in BFU-E in the peripheral blood of
ID mice with reduced serum IGF-I compared with
ontrol littermates (Figure 3). These ﬁndings suggest
hat hematopoietic progenitors of both myeloid and
rythroid lineages can egress from the bone marrow
nto the peripheral blood of LID mice, but in the
nvironment of reduced serum IGF-I, the progenitors
annot migrate into the spleen; this results in an ac-
umulation of progenitors in the circulation.
To conﬁrm these ﬁndings, we attempted to cor-
ect the IGF-I defect and associated depression in
plenic hematopoiesis in LID mice through a short-
ourse administration of exogenous recombinant hu-
an IGF-I (1 mg/kg/d for 4 days). The results are
resented in Figure 4A. Administration of IGF-I for 4
ays increased the number of splenic hematopoietic
rogenitors in LID mice compared with LID mice
hat received vehicle only (CFU-GM; P  .001). At
he same time, no signiﬁcant changes in bone marrow
ellularity or hematopoietic progenitor cell content
ere observed (Figure 4B). These results demonstrate
hat correction of circulating IGF-I levels can restore
he myeloid compartment in the spleen of LID mice.
ISCUSSION
In this study, we have shown that in the LID mice,
hich exhibit low circulating IGF-I and high circu-
35
l
c
t
t
s
w
w
m
p
m
i
s
c
r
r
f
b
a
p
n
a
h
a
c
I
t
[
h
w
m
m
I
a
L. A. Welniak et al.
3ating GH levels, myeloid progenitors had a signiﬁ-
ant decrease in the spleen but increased numbers in
he bone marrow and peripheral blood. Administra-
ion of exogenous IGF-I restored the number of
plenic hematopoietic progenitors comparable to
ild-type levels. Given the normal growth and body
eight in LID animals and the presence of IGF-I
essenger RNA (mRNA) in the spleen [5], the data
resented in this study suggest that circulating IGF-I
ay mediate the movement of myeloid progenitors
nto the spleen or allow for their maintenance in the
pleen.
A recent study demonstrated the efﬁcacy of re-
ombinant human GH as a mobilizing agent for pe-
ipheral blood stem cell collection when added to
ecombinant human granulocyte colony-stimulating
actor in patients who did not achieve adequate mo-
ilization with conventional protocols [16]. Of note, c
6lthough there were no signiﬁcant increases in the
eak white blood cell count compared with recombi-
ant human granulocyte colony-stimulating factor
lone, the combined treatment yielded signiﬁcantly
igher numbers of blood CD34 cells and primitive
nd myeloid progenitors.
Previous studies have examined the effect of in-
reased GH concentrations on murine hematopoiesis.
n those studies, increased serum GH was maintained
hrough constitutive expression in transgenic models
12] or by systemic administration of recombinant
uman GH [9,11]. Comparison of the transgenic mice
ith high levels of both GH and IGF-I to the LID
ice with high GH and low serum IGF-I reveals
arked differences that suggest a role for circulating
GF-I in splenic hematopoiesis. In the GH transgenic
nimals, splenic hematopoiesis was enhanced; in-
igure 2. Increased myeloid progenitors in the bone marrow of
ID mice. A, Total number of nucleated cells per femur in LID and
ontrol mice. B, Frequency of committed myeloid (CFU-GM; P 
05) and erythroid (BFU-E) progenitors and primitive progenitors
CFU-HPP; P .005) in the bone marrow of LID mice and control
ittermates. C, The total number of CFU-GM (P  .005), BFU-E,
nd CFU-HPP (P .01) per femur in LIDmice was compared with
hat in control littermates. Results of 4 independent experiments
ith a combined total of 7 mice per group are shown.F
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IGF-I and Splenic Hematopoiesis in Mice
Bnd day 10 colony-forming units–spleen were noted
5]. A high proportion of myeloid progenitors were in
ycle compared with controls [5]. In the bone marrow,
hich is 100% cellular in healthy young mice, hema-
opoiesis was only minimally perturbed with only in-
reased megakaryocyte progenitors and an increase in
he in vivo proliferation index [5]. We observed that
ID mice, with high serum GH levels and low serum
GF-I, exhibit decreased splenic myelopoiesis and
ormoplastic bone marrow with increased myeloid
nd immature (CFU-HPP) progenitors, as well as
ncreased megakaryocytes. On the basis of the cumu-
ative observations in GH transgenic [5] and LID
ice, it seems that the increase in hematopoiesis is
ost likely a direct result of increased GH levels or
ncreased localized production of IGF-I. Given that
e observed no evidence of blocked passage of my-
loid or erythroid progenitors from the bone marrow
o the periphery in either LID mice or control mice,
igure 3. Increased myeloid progenitors in peripheral blood of LID
ice. The total number of CFU-GM and BFU-E per milliliter of
eripheral blood was compared in 4-week-old male littermates.
esults of 3 independent experiments with a combined total of 5
ice per group are shown.irculating IGF-I does not seem to affect egress of t
B&MThese cells from the marrow space. However, migra-
ion of myeloid progenitors into the spleen does seem
o be dependent on the presence of adequate levels of
irculating IGF-I. An alternate explanation that can-
ot be fully ruled out is that maintenance of myeloid
rogenitors in the spleen is dependent on circulating
GF-I, although this is less likely given the localized
roduction of IGF-I mRNA in spleen [5].
Loss of CD44 expression has been shown to result
n an impaired migration of hematopoietic progeni-
ors from the bone marrow into the bloodstream and
ubsequent homing to the spleen in mice [17]. In
ontrast, activation of some isoforms of CD44 has
een shown to occur on stimulation of cells with
GF-I [18]. To date, no published studies have exam-
igure 4. Restoration of splenic hematopoietic progenitors in LID
ice after IGF-I administration. The total number of CFU-GM
er spleen and bone marrow in mice treated with IGF-I (1 mg/kg
wice daily for 3 days, subcutaneously; 4 mice per treatment) or
hosphate-buffered saline (PBS; twice daily for 3 days, subcutane-
usly; 2 mice per treatment) was determined the day after comple-
ion of cytokine administration. A, Signiﬁcant increases in splenic
FU-GM (P  .001) were observed in IGF-I–treated LID mice
ompared with LID mice that received PBS as a vehicle control. B,
o signiﬁcant differences in CFU-GM content were observed in
he femurs of IGF-I–treated LID mice compared with LID mice
hat received PBS as a vehicle control.
37
i
a
i
h
r
e
n
W
r
i
m
m
p
I
m
t
a
c
b
b
e
c
t
t
p
t
f
c
b
g
n
c
c
I
u
a
m
e
a
s
I
T
m
q
m
l
t
w
d
m
p
c
t
I
d
i
I
i
a
m
A
f
t
C
e
T
s
R
1
1
1
L. A. Welniak et al.
3ned the effect of IGF-I stimulation on CD44 or other
dhesion molecules on hematopoietic stem or progen-
tor cells. However, previous studies have shown en-
anced lymphocyte homing to lymphoid tissues after
ecombinant human GH administration [19]. How-
ver, in the LID mice, no defect in splenic lymphocyte
umber or splenic architecture was observed.
hether this inconsistency is due to differences or the
elatively short-term time frame of hormone admin-
stration versus congenital abnormalities is undeter-
ined. It should be noted that in CD44-deﬁcient
ice, lymphocyte homing and function are also ap-
arently unaffected [17]. Other potential targets for
GF-I modulation of molecules that affect homing are
embers of the integrin family, stromal-derived fac-
or-1, CXCR4, vascular endothelial growth factor,
nd metalloproteinases. Inhibition of Gi-coupled re-
eptors on bone marrow cells with pertussis toxin
efore transplantation can block homing to the spleen,
ut not bone marrow [20]. Although no evidence
xists to suggest that IGF-I acts indirectly through
hemokines in hematopoietic cells, IGF-I may act
hrough 1 or more molecules to inhibit migration into
he spleen. Both chemokine receptors and CD44 are
ossible targets on the basis of the studies discussed in
his article. IGF-I has been shown to activate integrin
amily members on other cell types [21–23]. The 4-
ontaining integrins are important mediators of mo-
ilization and homing of hematopoietic stem and pro-
enitor cells from and to the bone marrow, although
ot the spleen [23]. Vascular endothelial growth factor
an stimulate mobilization, and its expression is de-
reased in LID mice [24] and restored with exogenous
GF-I administration [25]. Similarly, IGF-I can mod-
late metalloproteinase activity, including matrix met-
lloproteinase-9 [26], another important regulator of
obilization.
Failure to support and maintain splenic myelopoi-
sis in mice with reduced circulating IGF-I is an
lternate explanation of the ﬁndings presented in this
tudy. Previous studies have demonstrated a role for
GF-I in the survival of myeloid progenitors [27,28].
he presence of IGF-I mRNA in the spleen of LID
ice has been previously reported [5]; however, ade-
uate levels of IGF-I for splenic, in contrast to bone
arrow, hematopoiesis could be dependent on circu-
ating, as well as paracrine, sources.
Myeloid and high proliferative potential progeni-
ors are decreased in the spleens of LID compared
ith control mice. We hypothesize that this maybe
ue to downregulation or deactivation of adhesion
olecules inhibiting the movement of cells out of the
eripheral blood and into the spleen. Although we
annot rule out that the low number of splenic hema-
opoietic progenitors is due to insufﬁcient levels of
GF-I protein in the spleen, IGF-I mRNA is pro-
8uced in the spleens of LID mice at greater levels than
n controls [5].
Therefore, these results suggest that circulating
GF-I is important in hematopoietic progenitor hom-
ng to the spleen in mice and may be of interest to
ssess its role with regard to mobilization and bone
arrow engraftment studies.
CKNOWLEDGMENTS
This project was funded in whole or in part with
ederal funds from the National Cancer Institute, Na-
ional Institutes of Health, under contract no. NO1-
O-12400. The authors gratefully acknowledge the
xpert technical assistance provided by Steve Stull and
anya Chanturya. We thank Laura Knott for out-
tanding secretarial services.
EFERENCES
1. Daughaday WH, Rotwein P. Insulin-like growth factors I and
II. Peptide, messenger ribonucleic acid and gene structures,
serum, and tissue concentrations. Endocr Rev. 1989;10:68-91.
2. Powell-Braxton L, Hollingshead P, Warburton C, et al. IGF-I
is required for normal embryonic growth in mice. Genes Dev.
1993;7:2609-2617.
3. Liu JP, Baker J, Perkins AS, Robertson EJ, Efstratiadis A. Mice
carrying null mutations of the genes encoding insulin-like
growth factor I (IGF-I) and type 1 IGF receptor (Igf1r). Cell.
1993;75:59-72.
4. Baker J, Liu JP, Robertson EJ, Efstratiadis A. Role of insulin-
like growth factors in embryonic and postnatal growth. Cell.
1993;75:73-82.
5. Yakar S, Liu JL, Stannard B, et al. Normal growth and devel-
opment in the absence of hepatic insulin-like growth factor I.
Proc Natl Acad Sci U S A. 1999;96:7324-7329.
6. Liu JL, Yakar S, LeRoith D. Conditional knockout of mouse
insulin-like growth factor-1 gene using the Cre/loxP system.
Proc Soc Exp Biol Med. 2000;223:344-351.
7. Ratajczak M, Kuczynski W, Onodera K, et al. A reappraisal of
the role of insulin-like growth factor I in the regulation of
human hematopoiesis. J Clin Invest. 1994;94:320-327.
8. French RA, Broussard SR, Meier WA, et al. Age-associated loss
of bone marrow hematopoietic cells is reversed by GH and
accompanies thymic reconstitution. Endocrinology. 2002;143:690-
699.
9. Murphy W, Tsarfaty G, Longo D. Growth hormone exerts
hematopoietic growth-promoting effects in vivo and partially
counteracts the myelosuppressive effects of azidothymidine.
Blood. 1992;80:1443-1447.
0. Tsarfaty G, Longo D, Murphy W. Human insulin-like growth
factor I exerts hematopoietic growth-promoting effects after in
vivo administration. Exp Hematol. 1994;22:1273-1277.
1. Tian ZG, Woody MA, Sun R, et al. Recombinant human
growth hormone promotes hematopoietic reconstitution after
syngeneic bone marrow transplantation in mice. Stem Cells.
1998;16:193-199.
2. Blazar BR, Brennan CA, Broxmeyer HE, Shultz LD, Vallera
DA. Transgenic mice expressing either bovine growth hor-
mone (bGH) or human GH releasing hormone (hGRH) have
11
1
1
1
1
1
2
2
2
2
2
2
2
2
2
IGF-I and Splenic Hematopoiesis in Mice
Bincreased splenic progenitor cell colony formation and DNA
synthesis in vitro and in vivo. Exp Hematol. 1995;23:1397-1406.
3. Dorshkind K, Horseman ND. The roles of prolactin, growth
hormone, insulin-like growth factor-I, and thyroid hormones in
lymphocyte development and function: insights from genetic
models of hormone and hormone receptor deﬁciency. Endocr
Rev. 2000;21:292-312.
4. Merchav S. The haematopoietic effects of growth hormone and
insulin-like growth factor-I. J Pediatr Endocrinol Metab. 1998;
11:677-685.
5. Montecino-Rodriguez E, Clark RG, Powell-Braxton L, Dorsh-
kind K. Primary B cell development is impaired in mice with
defects of the pituitary/thyroid axis. J Immunol. 1997;159:2712-
2719.
6. Carlo-Stella C, Nicola MD, Guidetti A, et al. Use of recombi-
nant human growth hormone (rhGH) plus recombinant human
granulocyte colony-stimulating factor (rhG-CSF) for the col-
lection of CD34 cells in poor mobilizers. Blood. 2002;100:
108a.
7. Schmits R, Filmus J, Gerwin N, et al. CD44 regulates hema-
topoietic progenitor distribution, granuloma formation, and
tumorigenicity. Blood. 1997;90:2217-2233.
8. Fichter M, Hinrichs R, Eissner G, Scheffer B, Classen S,
Uefﬁng M. Expression of CD44 isoforms in neuroblastoma
cells is regulated by PI 3- kinase and protein kinase C. Oncogene.
1997;14:2817-2824.
9. Murphy W, Durum S, Longo D. Human growth hormone
promotes engraftment of murine or human T cells in severe
combined immunodeﬁcient mice. Proc Natl Acad Sci U S A.
1992;89:4481-4485.
0. Wiesmann A, Spangrude GJ. Marrow engraftment of hemato-
poietic stem and progenitor cells is independent of Galphai-
coupled chemokine receptors. Exp Hematol. 1999;27:946-955.B&MT1. Hermanto U, Zong CS, Li W, Wang LH. RACK1, an insulin-
like growth factor I (IGF-I) receptor-interacting protein, mod-
ulates IGF-I-dependent integrin signaling and promotes cell
spreading and contact with extracellular matrix. Mol Cell Biol.
2002;22:2345-2365.
2. Loeser RF. Growth factor regulation of chondrocyte integrins.
Differential effects of insulin-like growth factor 1 and trans-
forming growth factor beta on alpha 1 beta 1 integrin expres-
sion and chondrocyte adhesion to type VI collagen. Arthritis
Rheum. 1997;40:270-276.
3. Ivankovic-Dikic I, Gronroos E, Blaukat A, Barth BU, Dikic I.
Pyk2 and FAK regulate neurite outgrowth induced by growth
factors and integrins. Nat Cell Biol. 2000;2:574-581.
4. Hattori K, Dias S, Heissig B, et al. Vascular endothelial growth
factor and angiopoietin-1 stimulate postnatal hematopoiesis by
recruitment of vasculogenic and hematopoietic stem cells. J Exp
Med. 2001;193:1005-1014.
5. Wu Y, Yakar S, Zhao L, Hennighausen L, LeRoith D. Circu-
lating insulin-like growth factor-I levels regulate colon cancer
growth and metastasis. Cancer Res. 2002;62:1030-1035.
6. Anne-Valerie R, Christelle D, Yannick F, Norbert P, Marc P,
Dominique H. Human growth hormone stimulates proteinase
activities of rabbit bone cells via IGF-I. Biochem Biophys Res
Commun. 2000;268:875-881.
7. Minshall C, Arkins S, Dantzer R, Freund GG, Kelley KW.
Phosphatidylinositol 3-kinase, but not S6-kinase, is required
for insulin-like growth factor-I and IL-4 to maintain expression
of Bcl-2 and promote survival of myeloid progenitors. J Immu-
nol. 1999;162:4542-4549.
8. Minshall C, Arkins S, Straza J, et al. IL-4 and insulin-like
growth factor-I inhibit the decline in Bcl-2 and promote the
survival of IL-3-deprived myeloid progenitors. J Immunol.
1997;159:1225-1232.39
